<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584801</url>
  </required_header>
  <id_info>
    <org_study_id>PMC-SLPCOPD-2020</org_study_id>
    <nct_id>NCT04584801</nct_id>
  </id_info>
  <brief_title>An Observational, Comparative, Multi Centre Study, Validating the Structured Light Plethysmography Against Standard of Care (Spirometry) in the Diagnosis of Chronic Obstructive Pulmonary Disease for Patients Who Plan to Undergo Spirometry Testing</brief_title>
  <acronym>SLPCOPD</acronym>
  <official_title>A Comparative, Non-randomised Study to Validate the Structured Light Plethysmography (SLP) Against Standard Diagnostic Method (Spirometry) for COPD for Patients Who Plan to Undergo Spirometry Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pneumacare Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pneumacare Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, comparative, multicentre study to validate the Thora3Di™ against&#xD;
      standard practice in patients who are undergoing investigation for COPD. The core methodology&#xD;
      involves capturing of data during a short period of measurement of breathing using SLP&#xD;
      against spirometric outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, comparative, multicentre study to validate the Thora3Di™ against&#xD;
      standard practice in patients who are undergoing investigation for COPD. The core methodology&#xD;
      involves capturing of data during a short period of measurement of breathing using SLP&#xD;
      against spirometric outcomes.&#xD;
&#xD;
      This study is a comparative study with two study visits (Part A and Part B ) to generate data&#xD;
      to characterise the tidal breathing patterns and parameters with Thora3Di™againt spirometry&#xD;
      FEV1/FVC and %predicted. Subjects will have a Part A visit 1(Development Phase), and a Part B&#xD;
      visit 2(Validation Phase) after developing algorithms for COPD diagnosis from Part A. At Part&#xD;
      A visit 1, subjects will have two 5-minute SLP measurements (Pre and Post bronchodilator). At&#xD;
      Part B visit 2, subjects will be seen in the clinics and have three 5-minute SLP measurements&#xD;
      (pre-bronchodilator, post-bronchodilator and post spirometry testing) along with spirometry&#xD;
      testing (pre-bronchodilator and post-bronchodilator). The SLP measurement should be performed&#xD;
      prior to standard lung function tests with minimal impact on clinical time and no change to&#xD;
      hospital attendance. Also, each visit subjects will be asked to report concomitant&#xD;
      medications and adverse events, and fill in COPD assessment test (CAT™).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Develop and Validate SLP parameters</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of points falling between the upper and lower 95% CIs of the Bland-Altman plot of the average of FEV1/FVC spirometer values and the output from the model using the SLP parameters against the difference between the spirometer values and their SLP parameter model counterparts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Agreement between SLP and Spirometry testing</measure>
    <time_frame>1 year</time_frame>
    <description>The agreement between COPD diagnosis classifications made by FEV1/FVC and from the model using SLP parameters will be assessed using the quadratic weighted Kappa statistic and F1 score.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>COPD</condition>
  <condition>Healthy Smoker</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <description>Development Phase Any adult (between 18 to 80 years old) who has been diagnosed with COPD guide GOLD criteria (FEV1/FVC ratio post bronchodilator &lt;0.70)&#xD;
Cohort A (N=50): COPD stage 1&#xD;
Cohort B (N=50): COPD stage 2&#xD;
Cohort C (N=50): COPD stage 3&#xD;
Cohort D (N=50): COPD stage 4&#xD;
Cohort E (N=50): Healthy Smokers (≥35 years old, current or ex-smoker with a history of ≥10 pack-years (20 cigarettes smoked per day for 1 year)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <description>Validation Phase&#xD;
Cohort A (N=50): COPD stage 1&#xD;
Cohort B (N=50): COPD stage 2&#xD;
Cohort C (N=50): COPD stage 3&#xD;
Cohort D (N=50): COPD stage 4&#xD;
Cohort E (N=50): Suspected COPD</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Structured Light Plethysmography</intervention_name>
    <description>Part A: Subjects will have two 5-minute SLP measurements (Pre and Post bronchodilator).&#xD;
Part B: Subjects will be seen in the clinics and have three 5-minute SLP measurements (pre-bronchodilator, post-bronchodilator and post spirometry testing).</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
    <other_name>Spirometry</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Part A&#xD;
&#xD;
          -  Cohort A (N=50): COPD stage 1&#xD;
&#xD;
          -  Cohort B (N=50): COPD stage 2&#xD;
&#xD;
          -  Cohort C (N=50): COPD stage 3&#xD;
&#xD;
          -  Cohort D (N=50): COPD stage 4&#xD;
&#xD;
          -  Cohort E (N=50): Healthy Smokers (≥35 years old, current or ex-smoker with a history&#xD;
             of ≥10 pack-years (20 cigarettes smoked per day for 1 year)&#xD;
&#xD;
        Part B&#xD;
&#xD;
          -  Cohort A (N=50): COPD stage 1&#xD;
&#xD;
          -  Cohort B (N=50): COPD stage 2&#xD;
&#xD;
          -  Cohort C (N=50): COPD stage 3&#xD;
&#xD;
          -  Cohort D (N=50): COPD stage 4&#xD;
&#xD;
          -  Cohort E (N=50): Suspected COPD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any adult (between 18 to 80 years old) who has been diagnosed with COPD guide GOLD&#xD;
             criteria (FEV1/FVC ratio post bronchodilator &lt;0.70)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history of myocardial infarct&#xD;
&#xD;
          -  Be unable to sit in an upright position for required period&#xD;
&#xD;
          -  Have significant co-morbidities (i.e. Chest work or spinal deformity, OSA, AHI &gt;30&#xD;
             secs&#xD;
&#xD;
          -  Any other significant disease or disorder which, in the opinion of the investigator,&#xD;
             may either put the participants at risk because of participation in the study, or may&#xD;
             influence the result of the study, or the participants' ability to participate in the&#xD;
             study&#xD;
&#xD;
          -  Height &gt; 194 cm&#xD;
&#xD;
          -  BMI &gt;40&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona Bafadhel, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oxford University Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis Wat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liverpool Heart and Chest Hospital NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brendan Cooper, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Walker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liverpool University Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richa Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Barts Health NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitra Shahidi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buckinghamshire Healthcare NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gin Lee</last_name>
    <phone>+44 1223 967418</phone>
    <email>gin.lee@pneumacare.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Wat, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Via UK NIHR website</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

